Molecular Allergen Based Diagnosis Impact on Clinical Efficacy of Aeroallergen Immunotherapy - a Pragmatic Randomized Clinical Trial

What this Trial Is About

Researchers are studying the use of allergen immunotherapy (AIT) for people with allergic rhinitis or asthma that do not fully respond to avoidance or medication. This research evaluates whether using a molecular-based allergy diagnosis improves the effectiveness of AIT compared to standard allergy testing. The study aims to better understand how matching allergen treatments to individual molecular sensitization patterns may impact treatment results. Participants are randomly assigned to one of two groups: one group receives immunotherapy based on standard allergy testing methods such as skin prick tests and specific IgE levels, while the other group's treatment decisions are guided by additional molecular allergen component testing using ImmunoCAP ISAC E112i. The study follows participants over a year to compare how these diagnostic approaches affect treatment outcomes. During the study, researchers will measure changes in combined symptom and medication scores, rhinitis symptoms, and control tests for allergic rhinitis and asthma at 24 and 52 weeks. Quality of life related to these conditions and patient opinions about immunotherapy will also be assessed. The study monitors participants' symptoms, medication use, and costs associated with treatment to evaluate the impact of molecular diagnosis on immunotherapy effectiveness.

Molecular Allergen Component Resolved Diagnosis to Decide Immunotherapy